Status:
COMPLETED
Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation
Lead Sponsor:
Samsung Medical Center
Conditions:
Neuroblastoma
Brain Tumor
Eligibility:
All Genders
Up to 15 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to investigate whether the prophylactic use of itraconazole is a better option than empirical use of itraconazole in the management (prevention and treatment) of fungal in...
Detailed Description
With the advance of chemoradiotherapy, survival of patients, especially children, with malignant disease has improved. However, prognosis is still poor with conventional chemotherapy if patients have ...
Eligibility Criteria
Inclusion
- Patients with high risk solid tumors who are going to receive high dose chemotherapy and autologous hematopoietic stem cell transplantation
Exclusion
- Significant organ toxicity (National Cancer Institute \[NCI\] grade \> 2) prior to high dose chemotherapy and autologous hematopoietic stem cell transplantation
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2008
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00336531
Start Date
April 1 2006
End Date
October 1 2008
Last Update
November 19 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical Center
Seoul, South Korea